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Neurodegenerative diseases (NDDs) involve years of gradual preclinical progression. It is widely anticipated
that in order to be effective, treatments should target early stages of disease, but we lack conceptual frame-
works to identify and treat early manifestations relevant to disease progression. Here we discuss evidence
that a focus on physiological features of neuronal subpopulations most vulnerable to NDDs, and how those
features are affected in disease, points to signaling pathways controlling excitation in selectively vulnerable
neurons, and tomechanisms regulating calcium and energy homeostasis. These hypotheses could be tested
in neuronal stress tests involving animal models or patient-derived iPS cells.Introduction
Neurodegenerative diseases (NDDs) involve protracted preclini-
cal phases that can last decades, and can include gradual build-
up of pathology selectively in those neurons that will degenerate
during end-stage disease (e.g., Saxena and Caroni, 2011). Sub-
sequent clinically detectable phases again last several years.
They involve relentless progression of neuronal pathology,
dysfunction, and degeneration leading to death. Although genes
whose mutations can cause a particular NDD are often ex-
pressed ubiquitously throughout life, each of these diseases
preferentially affects comparable and defined subpopulations
of neurons (selective neuronal vulnerability), leading to the
typical age-related clinical profile of each NDD. For some
NDDs (e.g., frontotemporal dementia and amyotrophic lateral
sclerosis [ALS]), the same mutations can cause distinct NDDs
in different individuals, or even combinations of NDDs in the
same individual, suggesting that although the systems affected
by particular mutations or insults can differ individually, the
spectrum of affected neurons is characteristic of each NDD
(Cooper-Knock et al., 2014; Deng et al., 2014).
This review will discuss and compare findings in Parkinson’s
disease (PD), spinal cerebellar ataxia (SCA), ALS, Huntington’s
disease (HD), and Alzheimer’s disease (AD). The physiological
features of the neurons selectively affected in these NDDs do
not exhibit obvious similarities, and the basis for their selective
vulnerabilities has remained poorly understood. Little is under-
stood about the factors that influence preclinical progression in
the neurons vulnerable to disease. While advancing age clearly
makes a key contribution (Jagust, 2013), external factors such
as damage to vasculature, inflammatory processes, and injuries
have been convincingly implicated (Zlokovic, 2005; Zacchigna
et al., 2008; Bjo¨rkqvist et al., 2009; Obermeier et al., 2013).
Notably, increasing disease-related pathology such as the accu-
mulation of characteristic protein deposits or mild cognitive
dysfunction does not invariantly progress to clinical disease.
The factors that predict clinical disease progression are again
poorly understood, but local deficits in energy metabolism andneuronal activity appear to predict progression (Palop et al.,
2006).
Despite major advances in dissecting genetic and cellular
mechanisms underlying NDDs, fundamental questions have
remained poorly understood. Two key unresolved issues are
as follows:
(1) We lack a conceptual framework to investigate how indi-
vidual pathogenic processes fit into a causal sequence of
relevant progressive dysfunctions during preclinical and
clinical phases of each disease.
(2) We lack a conceptual framework to investigate the mech-
anistic basis of selective neuronal vulnerability in NDDs.
In this Perspective, we hypothesize that these two issues
might be related, and that understanding factors underlying
selective neuronal vulnerability might provide much needed
guiding principles to unravel the logics of pathogenic process
progression. Accordingly, we focus first on what might deter-
mine selective neuronal vulnerability in NDDs.
The gradual nature of preclinical and clinical disease progres-
sion processes at least in some NDDs selectively in vulnerable
neurons (Saxena and Caroni, 2011) suggests that, at its core,
disease progression might involve slow but relentless reduction
of cell fitness in vulnerable neurons. This interpretation is sup-
ported by findings in animal models of ALS in which interventions
that reduce pathology mainly slowed down progression of dis-
ease manifestations during treatment, suggesting that key dis-
ease-driving processes can continue to progress in the absence
of prominent pathology, e.g., macroscopic protein deposits
(Saxena et al., 2013). Likewise, transient pathology-enhancing
treatments had little influence on the time course of disease
progression after treatment termination. These observations
suggest that NDDs might involve slowly progressing fitness
impairing processes in vulnerable neurons whose detection
can be challenging, and which can be accompanied by a variety
of secondary pathological processes (e.g., accumulation ofNeuron 85, March 4, 2015 ª2015 Elsevier Inc. 901
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lead to important disease manifestations, but only have modest
roles on disease progression. Accordingly, the study of causal
relationships in neurodegenerative diseases is complicated by
the fact that prominent disease manifestations might not have
critical roles in disease progression.
Interestingly, although individual NDDs mostly affect different
neurons and brain systems, subcellular targets of pathology
such as mitochondria, autophagy, ER stress, and proteostasis
have been reported in many of those diseases (Lin and Beal,
2006; Chan et al., 2009; Saxena and Caroni, 2011; Jagust,
2013; Hetz and Mollereau, 2014). This suggests that individual
NDDs might not be specifically linked to unique forms of subcel-
lular pathology. Taken together, these considerations suggest
that selective vulnerability might involve molecular pathways
specific to a particular NDD, affecting key homeostatic pro-
cesses in susceptible neuronal subpopulations. To explore this
notion, we focus on what might be specific functional and
homeostatic properties of neurons most affected in each
particular NDD, and how those properties are affected during
disease progression. Our analysis reveals common themes
involving early silencing and alterations in the excitability of
vulnerable neurons in NDDs. We suggest that, where it has
been detected, enhanced excitability early in disease might be
an adaptive response to boost neuroprotection in affected
neurons (‘‘acquired neuroprotection’’; Bas-Orth and Bading,
2013; Saxena et al., 2013). Whether enhanced excitability might
also, or possibly even predominantly, be a maladaptive conse-
quence of disease remains to be determined.
Parkinson’s Disease
PD, the second most common neurodegenerative disease, is
predominantly, but not exclusively, a movement disorder. Early
clinical manifestations typically include tremor at rest, rigidity,
and difficulties in the initiation and control of movements, partic-
ularly gait. Additional symptoms include alterations in sensation,
cognition, mood, and sleep. Substantia nigra pars compacta
(SNc) dopaminergic (DA) are selectively vulnerable to PD.
Typical PD pathology includes Lewy bodies with a-synuclein de-
posits. Causes of familial PD include mutations in a-Synuclein,
parkin, LRRK2, PINK1, and DJ1.
SNc DA neurons selectively affected in PD exhibit unusual
firing patterns in vivo, consisting of highly regulated phasic
bursts superimposed onto autonomous tonic pacemaker activity
(Schiemann et al., 2012). At least for ventral tegmental area DA
neurons, tonic firing regulation might modulate the saliency of
DA signals released at bursts (Goto et al., 2007). Tight negative
regulation of SNc DA neuron burst firing depends on high-level
expression of the small-conductance calcium-activated potas-
sium channel SK3 (Stocker, 2004) and K-ATP channels in vulner-
able nigral neurons (Wolfart et al., 2001; Wolfart and Roeper,
2002; Blythe et al., 2009; Schiemann et al., 2012). The balance
between tonic and phasic firing is influenced by SK3, and
expression of human mutant SK3 in DA neurons leads to
enhanced phasic firing by these neurons (Soden et al., 2013).
Pacemaking activity in adult SNc DA neurons is robust and likely
depends on several ion channels, whereas pacemaking in juve-
nile SNc DA neurons depends on sodium and hyperpolarization-902 Neuron 85, March 4, 2015 ª2015 Elsevier Inc.activated cyclic nucleotide-gated channels (Chan et al., 2007;
Guzman et al., 2009). Furthermore, burst firing in SNc DA neu-
rons depends on glutamatergic gating involving activation of
NMDA receptors interacting with voltage-sensitive ion channels
to overcome the inhibitory effects of the calcium-dependent
conductance of SK3 (Deister et al., 2009). Possibly as a way to
achieve fast calcium-dependent regulation of firing, SNc
DA neurons exhibit low cytosolic calcium buffering capacity
(Foehring et al., 2009), which might put them at risk for
calcium-dependent mitochondrial overload and pathology in
neurodegeneration (Chan et al., 2009). In summary, vulnerable
SNc DA neurons exhibit unusually intense, highly regulated firing
properties that depend on fast oscillations in cytosolic calcium
levels and on a high supply of energy sources (Figure 1).
Several genetic and pharmacological animal models of PD
target mitochondrial function, leading to elevated cytosolic
calcium levels and reduced excitability of vulnerable SNc DA
neurons (Chan et al., 2009; Surmeier et al., 2010; Guzman
et al., 2010; Surmeier et al., 2012; Masi et al., 2013; Hirsch
et al., 2013). The resulting silencing of vulnerable neurons in-
volves both burst and pacemaking firing and precedes neuronal
degeneration (Good et al., 2011; Michel et al., 2013). Consistent
with the existence of a causal relationship between hyperpolar-
ization and degeneration, inhibition of slow potassium conduc-
tances or activation of sodium channels in vulnerable neurons
is neuroprotective against genetic and toxic insults (Salthun-Las-
salle et al., 2004; Chan et al., 2007; Alvarez-Fischer et al., 2013).
Greatly reduced firing before degeneration might account for
the poor correlation between dysfunction and neuronal losses
in PD. Notably, surviving DA neurons in PD exhibit increased
NMDA receptor subunit NR1 and K-ATP subunit expression,
and display up to 2-fold enhanced bursting rates. These studies
suggest that enhanced in vivo burst firing might contribute to the
selective vulnerability of DA SNc neurons, possibly reflecting an
acquired vulnerability process (Liss et al., 2005; Schiemann
et al., 2012; Subramaniam et al., 2014). Taken together, several
studies suggest that vulnerable SNc DA neurons exhibit reduced
excitation due to reduced mitochondrial function and enhanced
cytosolic calcium levels in PD, leading to silencing and subse-
quent degeneration of vulnerable neurons (Figure 1). In addition,
enhanced excitability in PD might aggravate the vulnerability of
DA SNc neurons.
Spinal Cerebellar Ataxia
SCA is a group of up to 60 genetic disorders involving poor
coordination of movement, including gait, hands, and speech.
Cerebellar cortex GABAergic Purkinje cells (PCs) are selectively
vulnerable in many forms of SCA. Several SCAs involve polyglut-
amine expansions; some forms are autosomal dominant,
whereas others (e.g., Friedreich ataxia, ataxia telangiectasia)
are autosomal recessive.
PCs particularly affected in SCA exhibit unusually intense
and complex firing properties, consisting of cycles alternating
between autonomous tonic activity, bursting activity, and
silent periods (Figure 1). This striking complexity of PC firing
is made possible by the expression of an array of calcium
channels and calcium-activated potassium channels (Swensen
and Bean, 2003; Foehring et al., 2009; Carter and Bean, 2011;
Figure 1. Physiological Features of Neurons
Particularly Vulnerable in PD, SCAs and ALS,
and How These Features Are Affected in
Disease
Top row: SNc DA neurons (left) highly vulnerable
to PD exhibit alternating pacemaker and bursting
activity (center). NMDA receptor activation and
inhibition of K-ATP channels are important to
drive bursting activity (red), and calcium-depen-
dent channels (e.g., SK) are important for
pacemaking activity (blue). PD (right) involves
mitochondrial pathology (yellow; reduced calcium
uptake indicated by smaller blue arrow), excess
cytosolic calcium (blue dots) and excess K channel
opening as a result of decreased ATP availability
and excess cytosolic calcium, leading to reduced
excitation (broad blue bar).
Middle row: PCs (left) particularly vulnerable to
SCAs exhibit alternations of pacemaking activity,
bursting activity, and no activity (center). PCs
exhibit high levels of cytosolic calcium buffers
(ovals), which are greatly reduced in disease (right,
yellow). Bursting is regulated in part by dendritic
calcium fluxes, whereas suppression of firing
involves K conductances. SCA (right) involves
elevated cytosolic calcium levels, and (at least
in SCA1) elevated SK activity, leading to greatly
reduced PC firing.
Lower row: spinal MNs (left) particularly vulnerable
in ALS exhibit high-threshold burst firing activity
(center). Burst firing is suppressed by K conduc-
tances (blue), particularly SK channels. ALS (right)
involves ER and mitochondrial pathology (yellow)
and elevated cytosolic calcium levels, leading to
suppression of MN firing.
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tant among them are P/Q-type voltage-gated calcium channels
(sustain spontaneous bursting and dendritic calcium spiking),
and T-type voltage-gated calcium channels, small-conductance
(SK) and large-conductance (BK) calcium-dependent potassium
channels. SK channels set the intrinsic firing frequency of PC
(Stocker, 2004), whereas BK channels regulate action potential
shape. Notably, the extremely large dendrites have a prominent
role in regulating neuronal excitability in PCs, where a dendritic
calcium spike terminates each burst (Womack and Khodakhah,
2004). The high reliance on calcium transients for regulating
excitability might be reflected in high expression levels of the
cytosolic calcium buffers parvalbumin and Calbindin-D28 in PC.
In ataxia models, PCs exhibit reduced spontaneous firing
long before the onset of clinical symptoms and degeneration
(Shakkottai et al., 2011). Indeed, enhanced excitability in the
targets of PCs (deep cerebellar nuclei neurons), an anticipated
consequence of insufficient PC-mediated inhibition, was suffi-
cient to cause cerebellar ataxia in the absence of PC degenera-
tion (Shakkottai et al., 2004). PC silencing in disease involves
reduced parallel fiber input strength through a postsynaptic
mechanism, and reduced intrinsic excitability, e.g., through
increased voltage-dependent potassium currents (Hourez
et al., 2011). In SCA13, potassium channel mutations were
sufficient to alter firing patterns and reduce excitatory input to
PCs (Irie et al., 2014), whereas in SCA1, delayed action potential
generation was reduced by 4-aminopyridine, suggesting that
it might be mediated by A-like potassium conductances (Inoueet al., 2001). Levels of the calciumbuffering proteins parvalbumin
and calbindin-D28 were reduced early in SCA2 (Hansen et al.,
2013), and treatments that alleviate ataxic symptoms and
decrease PC pathology increased PC calbindin-D28 levels
(Vig et al., 2012). Furthermore, suppressing calbindin-D28
expression was sufficient to exacerbate disease in a mouse
model of SCA1 (Vig et al., 2012). Notably, restoration of
normal firing properties or increasing PC excitability prevented
PC degeneration (Hourez et al., 2011). Taken together, these
observations suggest that PCs selectively vulnerable to
SCA exhibit unusually complex and highly regulated firing prop-
erties, including high-frequency basal firing, complex bursts, and
firing suppression, which are all critically involved in how PCs
regulate sensory-motor integration in behavior, and which
involve somatic and dendritic regulation through calcium fluxes
(Figure 1). PC calcium buffers and firing are lost early in disease,
leading to ataxia symptoms and to late degeneration of PCs
(Figure 1).
Amyotrophic Lateral Sclerosis
ALS (a.k.a. Lou Gehrig’s disease), the most common form of
motoneuron disease, leads to progressive paralysis of skeletal
muscles. The disease can start at limbs or at facial muscles.
Spinal alpha-motoneurons (MNs), and upper motoneurons in
brainstem and motor cortex are selectively vulnerable to ALS.
Typical ALS pathology includes deposits enriched in ubiquitin,
TDP-43, FUS, and SOD1. Causes of familial ALS include muta-
tions in SOD1, C9ORF72, TDP-43, FUS, VAPB, and VCP.Neuron 85, March 4, 2015 ª2015 Elsevier Inc. 903
Figure 2. Non-Cell-Autonomous Loss of Firing in Vulnerable
Neurons in HD and SMA
Upper row: MSNs particularly vulnerable to HD exhibit tightly controlled epi-
sodes of firing, driven by neuromodulators and cortical inputs (left). In HD
(center and right), cortical inputs weaken (center), and then are lost (right),
leading to loss of excitation and degeneration in particularly vulnerable MSNs
(right, orange).
Lower row: spinal MNs particularly vulnerable to SMA exhibit burst firing that
depends on multiple excitatory inputs, including propiosensory Ia afferents
and spinal interneurons (left). In SMA (center and right), Ia afferents and
interneuron inputs weaken (center) and are then lost (right), leading to loss of
excitation and degeneration of MNs (orange).
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thus the behavioral output of the nervous system. To achieve
this, their firing properties are under tight and complex regulatory
control (Figures 1 and 2). Individual spinal MNs receive tens of
thousands of synaptic inputs from a high number of distinct
neuronal sources (Kanning et al., 2010; Deardorff et al., 2013).
Those inputs are not sufficient to drive MN spiking, which is
gated by neuromodulators. Among alpha-MNs, fast-fatigable
MNs are particularly vulnerable to ALS. They exhibit highest
thresholds for excitation, are recruited infrequently to produce
brief and intense force, fire in bursts, and might express higher
levels of calcium-activated SK channels (Saxena and Caroni,
2011; Mu¨ller et al., 2014). In contrast, least vulnerable slow
MNs exhibit low recruitment thresholds, are recruited frequently
during wakefulness, and exhibit tonic firing. Reflecting fast regu-
lation through intracellular calcium transients, vulnerable alpha-
MNs express low levels of cytosolic calcium buffering proteins
and are subjected to large and fast calcium fluxes across intra-
cellular organelles such as mitochondria and smooth ER (Kan-
ning et al., 2010). Finally, alpha-MNs exhibit particularly large
dendritic trees, and the most vulnerable fast-fatigable MNs
innervate particularly large numbers of muscle fibers (Saxena
and Caroni, 2011). Taken together, the most vulnerable MNs
exhibit highest recruitment thresholds, firing rarely, and in bursts.
Large intracellular calcium fluxes and large numbers of neuro-
muscular junctions lead to particularly high energetic demands
for function in these neurons.904 Neuron 85, March 4, 2015 ª2015 Elsevier Inc.Fast-fatigable MNs exhibit early pathology and loss of function
followed by peripheral denervation in mutant-SOD1 mouse
models of ALS (Saxena and Caroni, 2011). Early loss of function
by fast-fatigable MNs was also reported in other models of
motoneuron disease and in human patients (Kanning et al.,
2010). In mutant SOD1 mice, MNs exhibit early hypo-excitability
and a fraction of them already fails to produce sustained firing
early in disease (Figure 1) (Saxena et al., 2013; Delestre´e et al.,
2014). Pathology is closely correlated with increases in cytosolic
calcium and downregulation of the ER calcium regulating protein
calreticulin. Furthermore, in mutant C9Orf72 ALS motoneurons
derived from patient iPS cells, repetitive firing induced by current
injections was reduced (Sareen et al., 2013). A recent study
provided evidence that enhancing MN excitability in ALS mice
delays pathology and extends survival, whereas reducing MN
excitability is sufficient to produce pathology and early denerva-
tion in more resistant slow MNs (Saxena et al., 2013). Notably,
similar early failure to produce firing activity was reported for
MNs in mouse and Drosophila models of spinal muscular
atrophy (SMA), a rapidly progressing early onset motoneuron
disease (Mentis et al., 2011). In the SMA model failures in MN
excitation involved defects in proprioceptive Ia synaptic excita-
tion of MNs, and MN degeneration could be rescued by either
direct activation of MNs or by correcting the mutation in primary
afferent proprioceptive neurons (Figure 2) (Lotti et al., 2012;
Imlach et al., 2012). These findings of how MNs are affected in
SMA are reminiscent of non-cell-autonomous mechanisms of
disease in HD, where loss of cortical input activity leads to inac-
tivation and degeneration of vulnerable medium spiny neurons
(see below).
Huntington’s Disease
HD is a genetic disorder affecting muscle coordination and
cognition. Early clinical manifestations typically include a lack
of coordination and of gait control, as well as jerky movements.
Cognitive disabilities are detected early in disease, and progress
to dementia; sleep disturbances are also common. Striatal
medium spiny GABAergic neurons (MSNs), particularly those
of the indirect pathway regulated through D2-type DA receptors,
are selectively vulnerable to HD. Typical HD pathology involves
inclusion bodies enriched in Huntingtin. HD is caused by CAG
expansions in the Huntingtin gene.
MSNs most vulnerable in HD exhibit highly controlled and
sparse spiking activities modulated by cortico-striatal up and
down states (Berke et al., 2004; Mahon et al., 2006). These
neurons receive thousands of weak cortical inputs, and exhibit
high-threshold firing properties gated by DA and NMDA receptor
activation (Shen et al., 2007; Pomata et al., 2008). The depen-
dence on a large numbers of excitatory inputs for activation
might render these neurons particularly vulnerable to loss of
cortical excitation.
Like in other NDDs, vulnerable MSNs receive less excitatory
drive long before they degenerate in HD (Cepeda et al., 2003;
Raymond et al., 2011). Furthermore, correlated burst firing
between MSN neurons is reduced in HD mouse models
(Miller et al., 2008). MSN neurons of the less affected direct
pathway (D1-type DA receptor) exhibit early hypercitability,
which might compensate for a reduced synaptic drive from
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and their axons projecting to subcortical targets including stria-
tum are compromised early in disease (Cepeda et al., 2003;
Spampanato et al., 2008). Notably, although cortical neuron
degeneration occurs after that of MSNs, reduced functionality
of cortical neurons is critical to MSN degeneration (Gu et al.,
2005; Xie et al., 2010). Thus, a recent targeted rescue study in
a mouse model of HD provided evidence that it is the combina-
tion of mutant Huntingtin in cortical neurons and in MSNs that
accounts for MSN degeneration and striatal dysfunction (Wang
et al., 2014). HD might therefore initially involve deficits in neu-
rons synapsing onto MSNs (Cummings et al., 2009; Thomas
et al., 2011), but the degeneration is then most pronounced
in MSNs (Cowan et al., 2008). In other words, mutant Huntingtin
might not be sufficient to cause loss of excitation and degener-
ation of MSNs in HD, but combined with loss of critical excitatory
inputs by cortical neurons, it then causes degeneration in MSNs
(Figure 2). In MSNs, mutant Huntingtin appears to impair mito-
chondrial function (Damiano et al., 2013), which might predis-
pose these neurons to vulnerability due to absence of excitation.
Alzheimer’s Disease
AD is the most common neurodegenerative disease, and the
most common cause of late-onset dementia. Early clinical man-
ifestations typically include short-term memory losses. As AD
advances, confusion, mood swings, apathy, and long-term
memory losses become more prevalent. Typical AD pathology
includes extracellular amyloid plaques enriched in beta amyloid
(Ab), and neurofibrillary tangles enriched in hyper-phosphory-
lated Tau. Causes of familial AD include mutations in APP and
Presenilins 1 and 2.
Unlike other major NDDs, AD does not seem to preferentially
target a particular subpopulation of neurons. Instead, interneu-
rons and principal neurons in a small number of cortical struc-
tures are affected early in disease, leading to characteristic
memory and cognitive deficits. While AD is generally associated
with reduced excitatory synaptic activity, hyperactivity of some
neurons is frequent very early in AD mice. This hyperactivity of
subsets of principal neurons appears to involve direct local
effects of soluble Ab, and reduced inhibition through parvalbu-
min-positive interneurons (Busche et al., 2012; Verret et al.,
2012). In mousemodels of AD, early disease stages involve com-
parable numbers of silent and hyperactive neurons, particularly
in the vicinity of amyloid plaques (Busche et al., 2008; Grien-
berger et al., 2012). Recent human neuroimaging data suggest
that resting-state functional connectivity strength is reduced in
patients with AD (Buckner et al., 2009; Gleichmann andMattson,
2010). Interestingly, Ab deposition from interstitial fluid initially
appears to be most pronounced near more functionally active
networks, where it then reduces network activity (Bero et al.,
2011, 2012); likewise, tau release from neurons is influenced
by neuronal activity (Yamada et al., 2014). Notably, IP3 receptor
signaling is dysregulated in AD model mice, and Ryanodine re-
ceptor is upregulated in AD-derived tissue, in AD mice, and
upon stress, leading to enhanced release of calcium into the
cytosol and decreased excitability due to activation of SK chan-
nels (Stutzmann et al., 2004, 2006; Liu et al., 2012; Demuro and
Parker, 2013). In sum, AD shares with other NDDs a loss ofneuronal activation long before neuronal degeneration, and
possibly also before loss of synapses (Gleichmann et al.,
2012). However, due to a relative lack of experimental data
concerning neuronal subpopulations particularly vulnerable to
AD, it is currently not possible to relate firing properties of
susceptible neurons to their silencing and degeneration in AD.
Selective Neuronal Vulnerability to Loss of Excitation
in Disease
A comparison of neurons particularly vulnerable to NDDs,
focusing on their physiological properties under healthy condi-
tions and in disease, reveals potentially interesting similarities
(Figures 1 and 2). Selectively vulnerable neurons exhibit narrowly
regulated firing properties, including powerful mechanisms to
prevent firing or constrain its patterns in response to specific sig-
nals. To implement tight regulatory demands on firing, vulnerable
neurons tend to exhibit high reliance on fast cytosolic calcium
signaling and/or high levels of intracellular calcium trafficking
(Chan et al., 2009; Hirsch et al., 2013). A comparison among
selectively vulnerable neurons suggests that they might achieve
tight regulation of firing through distinct signaling strategies
involving calcium regulation. Thus, MNs and SNc DA neurons
exhibit low levels of intracellular calcium buffers, and high reli-
ance on mitochondria for rapid termination of calcium signals,
whereas PCs exhibit high reliance on calcium release from the
ER for signaling, and exceptionally high contents of cytosolic
calcium buffers for signal termination. We suggest that while
calcium codes might differ in the different types of vulnerable
neurons, what might render them particularly susceptible to
disease is their high dependence on proper cellular homeostasis
for both excitation and acquired neuroprotection through cal-
cium signaling pathways. Consistent with this notion, selectively
vulnerable neurons tend to lose firing activity before detection
of clinical manifestations. Furthermore, increased neuronal
excitability early in disease might be a compensatory mecha-
nism to provide critical neuroprotection to affected neurons.
A selective loss of excitation can have an important role in aggra-
vating disease progression both in vulnerable neurons and
through consequences of neuronal dysfunction for network
performance and behavior (Palop et al., 2006; Gleichmann and
Mattson, 2010). Furthermore, loss of excitation can be a cell-
autonomous process in neurons that will degenerate, or can be
due to disease-related activity deficits in critical input neurons.
In both cases, lack of excitation can promote disease-related
degeneration in vulnerable neurons, suggesting that the combi-
nation of disease-related vulnerability and loss of excitation can
have a major role in driving disease.
Although similarities among vulnerable neurons as highlighted
above are suggestive, whether they reflect appropriate classifi-
cations and are indeed relevant to disease remains to be deter-
mined. Thus, in the absence of experimental evidence directly
investigating causal relationships between selective neuronal
vulnerability to particular NDDs and intrinsic neuronal mecha-
nisms relating control of excitation to intracellular signaling,
as well as between disease-related disruption of excitation in
vulnerable neurons and disease progression, apparent aspects
of commonality as emphasized above might be anecdotal.
Furthermore, the role of enhanced excitability in NDDs hasNeuron 85, March 4, 2015 ª2015 Elsevier Inc. 905
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excess excitation as a major factor in disease progression
(e.g., Mattson, 2003; Chan et al., 2009). Nevertheless, two ques-
tions warrant further consideration at this point: (1) what disease-
related mechanismsmight render selectively vulnerable neurons
particularly prone to loss of excitation, and (2) how loss of
excitation might aggravate disease progression in vulnerable
neurons. It should be noted that in the absence of a disease
context, e.g., expression of a disease-causing mutant, suppres-
sion of excitation or enhancement of cell stress were not
sufficient to produce pathology and degeneration in vulnerable
neurons (Saxena et al., 2013). In good agreement with the frame-
work described above, this suggests that early disease-related
processes specifically compromise subpopulations of vulner-
able neurons in disease, rendering these neurons particularly
sensitive to loss of excitation, and dependent on excitability for
neuroprotection.
What cellular pathogenic mechanisms associated with NDDs
might lead to disruption and loss of excitation in vulnerable
neurons? Direct reductions in the strength of excitatory inputs,
e.g., through alterations in glutamate receptor regulation, or in
individual pathways supporting neuronal excitability might not
persistently lead to loss of excitation because of homeostatic
mechanisms aimed at adjusting the strength of neuronal inputs
within values consistent with network function. In contrast, dis-
ease processes targeting basic cellular mechanisms coupled
to neuronal excitability should have major consequences on
neuronal excitation. Among them, persistent enhancements in
neuronal cytosolic calcium levels and/or deficits in energy pro-
duction can suppress excitability through calcium-dependent
potassium conductances and have been frequently associated
with NDDs and with disease-related pathological processes
(Chan et al., 2009; Hirsch et al., 2013). Calcium homeostasis
interfaces with proteostasis mechanisms at ER and Golgi mem-
branes, and with most major intracellular signaling pathways
(Lin and Beal, 2006; Bading, 2013; Hetz and Mollereau, 2014).
Accordingly, its disruption can have powerful negative conse-
quences on neuronal homeostasis mechanisms. Candidate
disease-related mechanisms that might target calcium homeo-
stasis include deficits in neuronal energy production, and deficits
in intracellular organelle systems that influence ion fluxes and
couple these processes to excitation. Consistent with this
notion, many pathogenic processes in NDDs appear to target
mitochondrial function and/or calcium metabolism, either
directly or indirectly (e.g., Lin and Beal, 2006; Chan et al.,
2009; Hirsch et al., 2013).
Several mechanisms could link loss of excitation to severe dis-
ease progression in vulnerable, partially compromised neurons.
At the synaptic level, reductions in the ratio of synaptic versus
extrasynaptic NMDA receptor activation have been shown to
impair neuroprotection and enhance processes that compro-
mise neuronal homeostasis (Bading, 2013). Thus, synaptic
NMDA receptor activation and burst firing enhance neuronal
functions and neuroprotection through a range of key mecha-
nisms, including nuclear calcium signaling and activation of
CREB-mediated gene expression, transport of the transcrip-
tional co-activator CRTC1 from synapse to nucleus, and activa-
tion of BDNF gene expression (Ghosh et al., 1994; Hardingham906 Neuron 85, March 4, 2015 ª2015 Elsevier Inc.et al., 2001; Zhang et al., 2007; Ch’ng et al., 2012; Bading,
2013; Karpova et al., 2013). Furthermore, several CREB target
genes have potent neuroprotective roles (Hardingham and Bad-
ing, 2010). In contrast, extrasynaptic NMDA receptor signaling,
which is frequently enhanced in NDDs (Milnerwood et al.,
2010), interferes with several neuroprotective pathways and
counteracts CREB activation (Hardingham et al., 2002; Xu
et al., 2009; Wang et al., 2013; Karpova et al., 2013; Parsons
and Raymond, 2014). Furthermore, patterns of neuronal firing
have major consequences on neuronal gene expression and
function (Xiang et al., 2007; Ma et al., 2011). Thus, tonic and
bursting firing patterns recruit distinct voltage-dependent cal-
cium channels and intracellular calcium-transporting organelles,
differentially modulating CREB-dependent gene expression
(Wheeler et al., 2012). Likewise, phasic and tonic firing patterns
can recruit different levels of key transcription factors such as
NFAT family members (Herna´ndez-Ochoa et al., 2007). Finally,
reductions in neuronal firing can cause calcium depletion from
ER stores, leading e.g., to ubiquitin-dependent degradation
of Sp4, a transcription factor involved in synaptic plasticity
(Lalonde et al., 2014). On the other hand, excess excitation can
have powerful toxic effects on neurons, e.g., in epilepsy and
stroke (Lai et al., 2014). The extent to which excess excitation
has a major role in NDDs has remained a complex issue (Yano
et al., 1998; Mattson, 2003; Soriano et al., 2006; Sasaki et al.,
2010), but one mechanism might involve a relative excess in
extrasynaptic NMDA receptor activation, through elevated ex-
trasynaptic receptor levels, elevated extrasynaptic glutamate
levels, and/or reduced synaptic NMDA receptor activation
(Okamoto et al., 2009; Milnerwood et al., 2010; Parsons and
Raymond, 2014).
Models
The observations outlined above can be combined into simpli-
fied general models of how disease-related mechanisms
affecting selectively vulnerable neurons might influence disease
progression in NDDs (Figure 3). Themodels are based on the key
role of excitation, e.g., through synaptic NMDA receptors, to pro-
mote neuroprotection, on observations that disease-causing
genes can affect cellular processes (e.g., mitochondrial homeo-
stasis) at the intersection between pathways controlling excit-
ability and supporting neuronal fitness, and on the narrow
reliance by vulnerable neurons on these two types of factors.
Although many of the premises require experimental validation
(see next section for example), these models might be useful
to formulate testable hypotheses about mechanisms of disease.
Studies on animal models of NDDs suggest that a first level of
specificity should relate disease-related mechanisms, e.g., the
molecular pathways affected by particular disease-causing
mutations, to a subset of the neurons that can be affected in
NDDs (Figure 3). This specificity might be defined by a match
between molecular mechanisms affected by disease-related
proteins and a particular reliance of targeted neurons on those
mechanisms (e.g., mitochondria in PD). A second requirement
of these models (second hit) is that, in vulnerable neurons, the
consequences of disease-related protein interference should
negatively impact critical mechanisms affecting excitation,
e.g., through calcium homeostasis (Figure 3; as discussed in
Figure 3. Model of How Disease-Relevant
Mutant Proteins and/or Local Lesions Lead
to NDDs Preferentially Affecting
Subpopulations of Vulnerable Neurons
A particular disease-relevant mutant protein and/
or a local insult affect neurons to varying degrees
(yellow shades), defining subpopulations of sen-
sitive neurons. Among sensitive neurons, those in
which excitation is highly sensitive to alterations
in the pathways affected by disease-relevant
mutations or insults (e.g., calcium and/or energy
homeostasis) are selectively vulnerable to disease
(dark yellow [NDD-1], or pink [NDD-2]). Disease
progression then involves age- and stress-
dependent loss of excitation, alterations in the
local microenvironment (e.g., vasculature, immune
cells, glia, interconnected neurons), leading to
clinical manifestations of disease. The schematic
further indicates that the same disease-related
agents can cause distinct NDDs (NDD-1 and/or
NDD-2) by initially (or preferentially) affecting
distinct subpopulations of selectively vulnerable
neurons in distinct individuals.
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ally to neurons selectively vulnerable in NDDs). Together, these
two specificity requirements should focus disease-related
processes to a specific (vulnerable) subset of those neurons in
which alterations in specific aspects of cellular (e.g., calcium
and/or energy) homeostasis readily lead to deficits in excitation.
Different NDDs would involve distinct subsets of neurons, but
some of the molecular mechanisms could be at the origin of
several distinct NDDs (Figure 3). The reduction in excitation
might lead to compensatory enhanced excitability, which in
this view would be adaptive, but could become maladaptive
(possibly leading to further acquired vulnerability, e.g., in PD).
A third critical step in disease progression would involve pro-
gressive reduction of excitation in vulnerable neurons, e.g., as
a function of age or increasing cell stress. This reduction might
involve intrinsic mechanisms, and/or disease-related losses in
critical excitatory inputs to vulnerable neurons (Figure 3). Loss
of excitation beyond a critical level might initiatemore severe dis-
ease progression, including degenerative processes in targeted
neurons, implication of local environment cells such asmicroglia,
astrocytes, and vasculature epithelial cells through stress re-
sponses and exosome-mediated spillover of disease-related
toxic products, and functional losses leading to clinically detect-
able symptoms of disease (Zacchigna et al., 2008; Ilieva et al.,
2009; Bjo¨rkqvist et al., 2009; Hetz and Mollereau, 2014).
Conclusions and Implications
Here we suggest that factors leading to NDDs (e.g., gain-of-
function mutations, or combinations of genetic background
and adverse factors such damage to local vasculature) might
compromise key cellular mechanisms that influence neuronal
excitability, and that the neurons particularly vulnerable to
NDDs might exhibit excitation-regulation features that put
them at higher risk for excitability loss and homeostasis imbal-
ance. Accordingly, intracellular pathways more likely to confer
risk factors for vulnerability to NDDs might involve cellular hubs
in which regulation of excitability and neuronal homeostasis
overlap in vulnerable neurons. Slow but relentless progressionmight involve a gradual increase in intrinsic and environment-
derived cellular stressors influenced by age in affected neurons.
In addition to diffusion and intracellular transport of toxic protein
species, spread of disease among interconnected neurons
might involve impairment of presynaptic excitation. Thus, initial
impairments in more vulnerable neuronal subpopulations in
the network might impose additional load on interconnected
subpopulations, enhancing their vulnerability in a disease
context. The model predicts that factors directly relevant to
disease progression should further decrease the dynamic range
of neuronal excitability regulation and homeostatic resilience
in vulnerable neurons. These predictions could be tested
in neuronal stress tests, in which physiological input-output
relationships of vulnerable neurons would be measured across
a range of increasingly challenging conditions. Likewise,
candidate interventions that might have an impact on disease
progression should restore the physiological responses of
vulnerable neurons in stress tests.
Regardless of the extent to which our analysis captures essen-
tial features of factors involved in NDD progression, we suggest
that much-needed advances in elucidating disease-driving
mechanisms in NDDs will depend on discovering disease-rele-
vant cellular targets of mutant proteins that cause particular
NDDs. So far, this has been challenging because individual
disease-relevant mutants have turned out to affect a confusing
variety of pathways in neurons. A focus on pathways that
influence excitability in vulnerable neurons might help to zoom
in on potentially relevant targets. This research could be carried
out in animal models based on human mutations that exhibit
slowly progressing neurodegeneration and mimic the corre-
sponding human disease. In addition, a potentially promising
option involves corresponding studies in vulnerable neurons
differentiated from patient-derived iPS cells. However, whether
those cultured iPS-derived neurons will reproduce relevant
features of the disease remains to be determined.
In conclusion, our comparison of neurons particularly affected
in NDDs suggests the existence of recurring themes involving
complex and often intense firing patterns, tight control ofNeuron 85, March 4, 2015 ª2015 Elsevier Inc. 907
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Perspectiveexcitation, and dynamic regulation of excitability relying on high
cytosolic calcium fluxes. We suggest that in a NDD setting these
factors put vulnerable neurons at risk for loss of excitation
through elevated cytosolic calcium levels, which in turn pro-
motes progression and spread of degeneration. Should its rele-
vance be validated, the framework discussed in this review
should serve to focus mechanistic studies of disease initiation
and progression on relevant core features of the disease pro-
cess. Likewise, a focus on supporting excitability pathways in
vulnerable neurons might lead to novel strategies to alleviate
symptoms and slow down progression in NDDs.
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